• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

How a Tyrosine Kinase Inhibitor Is Giving Hope to Lung Cancer Patients

by Bellbrook Labs / Tuesday, 20 August 2019 / Published in Emerging Targets
tyrosine kinase inhibitor lung cancer

According to the American Cancer Society, lung cancer is the leading cause of cancer death each year and accounts for approximately 13% of all new cases. The most common type being non-small cell lung cancer (NSCLC). Although smoking is the biggest contributor, other factors such as genetics and environmental pollutants contribute to lung cancer of all types. However, for those living with the disease, treatment is more of a concern and reasonably so. Like with other cancers, the choice of treatment whether surgical, radiation, chemotherapy or targeted drug therapy, depends on how far along the cancer is and the type.¹  Epidermal growth factor receptor (EGFR) a receptor tyrosine kinase, is of particular interest due to its role in cell growth and division. Mutations in EGFR and/or its cell signaling pathway result in several types of cancer including lung cancer.

Role of a Tyrosine Kinase Inhibitor in Targeted Drug Therapy

Researchers have found a few mutated genes in NSCLC patients; therefore targeting these genes for treatment is a priority. For example, patients with mutations in EGFR are more sensitive to EGFR inhibitor therapies.²  More specifically, mutations found in the tyrosine domain of EGFR can be targeted with an EGFR tyrosine kinase inhibitor such as gefitinib (a first-generation EGFR inhibitor).³ Compared to standard chemotherapy, gefitinib was found to be more effective in patients with advanced NSCLC harboring sensitive EGFR mutations.³

Over the years there have been improvements made that developed into second-generation EGFR tyrosine kinase inhibitor such as dacomitinib which has demonstrated both progression-free survival and overall survival when given as first-line therapy to NSCLC patients.4 Drug resistance to first-generation EGFR inhibitors made improvements necessary in some cases in order to keep cancer at bay.

A multitude of research and subsequent clinical trials are done to compare the various drug options. Other than determining how to better identify patients with a high chance of benefiting from EGFR inhibitors, some of the objectives of the research are as follows:

  • Effectiveness
  • Toxicity
  • Side effects
  • Ability to be multi-targeted

Although dacomitinib appears to be an important first-line agent in EGFR-mutated NSCLC, there are increased side effects of diarrhea, rash, stomatitis, and paronychia compared with first-generation EGFR inhibitors.4 However, if the patient can handle the side effects, the enhanced survival rate is worth it.


Learn how to determine drug-target residence times for EGFR inhibitors with this guide from BellBrook Labs.

A Guide to Measuring Drug-Target Residences Times with Biochemical Assays

Get the Guide


References

  1. About Non-Small Cell Lung Cancer. What Is Non-Small Cell Lung Cancer? :1-14. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html
  2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR. N Engl J Med. 2010;362(25):2380-2388. doi:10.1056/NEJMoa0909530
  3. Growth SE, Receptor F. Oncologist. 2007:325-330. doi:10.1634/theoncologist.12-3-325
  4. Lau, S.C.M., Batra, U., Mok, T.S.K. et al. Drugs (2019) 79: 823. https://doi.org/10.1007/s40265-019-01115-y
  5. Mok TS, Cheng Y, Zhou X, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244-2250. doi:10.1200/JCO.2018.78.7994
Tagged under: kinase assay, Transcreener ADP Kinase Assay, tyrosine kinase inhibitors

What you can read next

Nanoparticles Target Cancer’s Sweet Spot
SIRT6: Keeping Tumor Cells in Check
Battling Lysosomal Storage Diseases with ERT and SRT

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP